retatrutide developer eli lilly Strengthens Its Weight Loss Pipeline. Why Could Be the Next Growth Driver for LLY New Eli Lilly drug retatrutide

Retatrutide shows higher discontinuation rates

Recruiting as of June 2026

The liver doesnt store and release excessive amounts of glucose when blood glucose levels are in a healthy range

Patients without significant cardiovascular disease who prioritize efficacy over regulatory approval status fit the Retatrutide profile well

The proportion of patients with PCOS who were prescribed semaglutide or tirzepatide increased more than 7-fold over the study period

It is commonly used in laboratory research focused on incretin signaling, metabolic regulation, and related pathways involved in glucose balance, energy expenditure, and weight regulation